Figure 9.

LC3B inhibition renders the tumor susceptible to anti-PDCD1-mediated anti-tumor immunity. (A) Western blot analysis of LC3B and NANOG expression in various mouse cancer cell lines. (B) Schematic of the therapy regimen in mice implanted with B16F10 cells. (C) Tumor growth, (D) mass at 20 d after challenge, and (E) the survival of the mice inoculated with B16F10 treated with the indicated reagents. (F) The frequency of apoptotic cells in the tumors of siGFP- or siLc3b #1-treated mice, with or without anti-PDCD1 treatment. (G) Flow cytometry profiles of tumor-infiltrating CD3⁺ and CD8A⁺ T cells. (H) The ratio of GZMB⁺ to tumor-infiltrating CD3⁺ CD8A⁺ T cells. (I) Quantification of antigen-specific CTLs in tumors (left), draining lymph nodes (middle), or spleens (right) derived from the tumor-bearing mice. For the in vivo experiments, 10 mice from each group were used. *p < 0.01 and **p < 0.001, by two-way ANOVA (C, D and F-I), or log-rank test (Mantel-Cox) (E). The data represent the mean ± SD